Stalevo (Carbidopa / Levodopa / Entacapone) - Published Studies

Stalevo Related Published Studies

Well-designed clinical trials related to Stalevo (Carbidopa / Levodopa / Entacapone)

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]

Other research related to Stalevo (Carbidopa / Levodopa / Entacapone)

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). [2008.10.31]

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. [2008.10.07]

Should levodopa dose be reduced when switched to stalevo? [2008.03]

[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life] [2008.01.30]

Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. [2007]

Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). [2006.09]

Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients. [2006.03]

Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. [2005.07]

An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. [2005.02]

Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). [2004.07]

Levodopa/carbidopa/entacapone (Stalevo). [2004.01.13]